CoChat

The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer

Open access

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

The BRAFV600E mutation is found in 8–10% of metastatic colorectal cancer (mCRC) patients and it is recognized as a poor prognostic factor with a median overall survival inferior to 20 months. At present, besides immune checkpoint inhibitors (CPIs) for those tumors with concomitant MSI-H status, recommended treatment options include cytotoxic chemotherapy + anti-VEGF in the first line setting, and a combination of EGFR and a BRAF inhibitor (cetuximab plus encorafenib) in second line. However, even with the latter targeted approach, acquired resistance limits the possibility of more than an incremental benefit and survival is still dismal. In this review, we discuss current treatment options for this subset of patients and perform a systematic review of ongoing clinical trials. Overall, we identified six emerging strategies: targeting MAPK pathway (monotherapy or combinations), targeting MAPK pathway combined with cytotoxic agents, intensive cytotoxic regimen combinations, targeted agents combined with CPIs, oxidative stress induction, and cytotoxic agents combined with antiangiogenic drugs and CPIs. In the future, the integration of new therapeutic strategies targeting key players in the BRAFV600E oncogenic pathways with current treatment approach based on cytotoxic chemotherapy and surgery is likely to redefine the treatment landscape of these CRC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13010137

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic representation of pathways currently under investigations as actionable therapeutic targets harnessing BRAFV600E mutant metastatic colorectal cancer (mCRC). Legend: mAb = monoclonal antibodies; i = inhibitor. Vit = vitamin. Mut = mutation.
Figure 1 Schematic representation of pathways currently under investigations as actionable therapeutic targets harnessing BRAFV600E mutant metastatic colorectal cancer (mCRC). Legend: mAb = monoclonal antibodies; i = inhibitor. Vit = vitamin. Mut = mutation.CC BY · PubMed Central
Figure 2 Current treatment options for BRAFV600E mutant metastatic colorectal cancer (mCRC). According to most recent studies, treatment opportunities for BRAFV600E mutant mCRC are fast developing if compared to only a decade ago. The panorama of treatment now includes the following options: surgery, combinations of cytotoxic drugs, targeted and immunological agents. All these approaches should be carefully evaluated when discussing the treatment approach to BRAFV600E mCRCs in multidisciplinary teams (MDT). Given the peculiarity of this subset of mCRCs, clinical trial enrolment should always be considered also in the upfront setting. Based on current evidence, MSI BRAFV600E mutant mCRC progressing to first line treatment with pembrolizumab should be managed as microsatellite stable (MSS) BRAFV600E mutant mCRC. Keys: * = Metastasectomy should be -considered in liver limited disease in case of response or prolonged disease control obtained with medical treatments even if relapse-free and overall survival is poorer than BRAF wild-type mCRCs. Legend: mCRC = metastatic colorectal cancer. SD = stable disease; PD = progressive disease; PR = partial response. “Dashed line” means consider. “Continuous line” means recommended.
Figure 2 Current treatment options for BRAFV600E mutant metastatic colorectal cancer (mCRC). According to most recent studies, treatment opportunities for BRAFV600E mutant mCRC are fast developing if compared to only a decade ago. The panorama of treatment now includes the following options: surgery, combinations of cytotoxic drugs, targeted and immunological agents. All these approaches should be carefully evaluated when discussing the treatment approach to BRAFV600E mCRCs in multidisciplinary teams (MDT). Given the peculiarity of this subset of mCRCs, clinical trial enrolment should always be considered also in the upfront setting. Based on current evidence, MSI BRAFV600E mutant mCRC progressing to first line treatment with pembrolizumab should be managed as microsatellite stable (MSS) BRAFV600E mutant mCRC. Keys: * = Metastasectomy should be -considered in liver limited disease in case of response or prolonged disease control obtained with medical treatments even if relapse-free and overall survival is poorer than BRAF wild-type mCRCs. Legend: mCRC = metastatic colorectal cancer. SD = stable disease; PD = progressive disease; PR = partial response. “Dashed line” means consider. “Continuous line” means recommended.CC BY · PubMed Central
Figure 3 PRISMA 2009 Flow diagram representing the systematic review performed on ClinicaTrial.gov on 23 December 2020 [65]. For more information, visit www.prisma-statement.org.
Figure 3 PRISMA 2009 Flow diagram representing the systematic review performed on ClinicaTrial.gov on 23 December 2020 [65]. For more information, visit www.prisma-statement.org.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Cited by

See all 74

Metadata

Authors
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., Siena, S., & Sartore-Bianchi, A.
Affiliations
  • University of Milan (IT)
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
  • Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milano, Italy
Venue
Cancers
Publisher
MDPI AG
Published
2021-01-04
Volume
13
Issue
1
Pages
137
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3119715349
Cited by
73
References
79
Citations by year
2026: 1 · 2025: 3 · 2024: 25 · 2023: 14 · 2022: 20 · 2021: 10
FWCI
2.09
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fondazione Regionale Ricerca Biomedica Regione Lombardia (Project CP 12/2018 IANG CRC)
  • H2020 grant agreement MoTriColor (no. 635342-2)
  • AIRC IG (no. 20685)
  • Terapia Molecolare Tumori by Fondazione Oncologia Niguarda Onlus (NA)
  • FONDAZIONE AIRC under 5 per Mille 2018 (ID. 21091 program)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
BRAF V600E mutation, metastatic colorectal cancer, MAPK signaling, cetuximab, encorafenib, immune checkpoint inhibitors, acquired drug resistance, anti-VEGF therapy, cytotoxic chemotherapy, oxidative stress, antiangiogenic drugs, combination therapy, clinical trials

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.3390/cancers13010137
The paper
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., Siena, S., & Sartore-Bianchi, A. (2021). The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers. https://doi.org/10.3390/cancers13010137

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.